ClinicalTrials.gg
Enrolling by invitationNCT06283498Updated Mar 18, 2025

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

An interventional study of Device Morpheus8V in Overactive Bladder Syndrome, sponsored by InMode MD Ltd.. Enrolling by invitation at 3 sites in 2 countries. Open to female participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by InMode MD Ltd. (part of InMode Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as enrolling by invitation.
  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.

Planned enrollment
190th of 288
32 · median 66
Started
2023
with 20 others
No phase
113 of 333
20 open now
Primary completion
2025-11
later than 7 of 47 live
Registered
299th of 333
by date

Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 190th largest by planned enrollment of the 288 interventional ones that give a count, is one of 21 that started in 2023, is one of 113 with no phase, reaches primary completion later than 7 of the 47 other live ones, and was the 299th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 21 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Urinary Bladder, Overactive with a site in United States, or all of them as a file.
02

Study summary

The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder

The main questions it aims to answer are:

•Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. [Time Frame: 3 months]

Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis.

Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment.

03

Conditions studied

  • Overactive Bladder Syndrome
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21-80 years old, inclusive
  • Subject is willing to provide , is geographically stable, understands the requirements for completing the bladder diary and is willing to comply with the required diary, follow-up visits, and testing schedules.
  • Urinary incontinence, predominant urgency incontinence for at least one episode on a 3-days diary.
  • Reporting at least "moderate bother" on Item 2 on the UDI, "Do you experience a strong feeling of urgency to empty your bladder" (on new patient paperwork)
  • >8 micturitions and >3 urgency episodes per 24 hours on a 3-day bladder diary (see Appendix 2)
  • 1 UUI episode on a 3-day bladder diary (see Appendix 2)
  • Not currently taking anti-muscarinic or beta3 agonist therapy (after at least a 2-week )
  • Post-void residual (PVR) ≤ 100 ml NOTE: it may include Subjects with a single PVR of >100 ml followed by two consecutive PVR measurements of ≤100 ml in the study. We will record the final acceptable PVR measurement in the data.
  • Ability and willingness to self-catheterize in case this is necessary.
  • With respect to their reproductive capacity must be or surgically sterile or willing to use a method with a failure rate of less than 1% per year when used consistently and correctly from screening until the last follow up

Exclusion criteria

Exclusion Criteria:

  • Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
  • Any permanent implant or an injected chemical substance in the treatment area.
  • Superficial areas that have been injected with HA/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
  • Current or history of cancer, or current condition of any other type of cancer, or premalignant moles.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy, the intention of pregnancy and nursing.
  • Impaired immune system due to diseases such as AIDS and , disorders, or use of immunosuppressive medications.
  • Patients with a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
  • Any active condition in the treatment area, such as sores, eczema, and rash.
  • History of vaginal disorders, keloids, abnormal wound healing.
  • History of bleeding coagulopathies or use of anticoagulants in the last 10 days, as per the practitioner's discretion.
  • Non-English speakers
  • Severely impaired mobility or cognition
  • Spinal cord injury or advanced/severe neurologic condition including Multiple Sclerosis, Parkinson's Disease
  • Repair of pelvic organ prolapse or incontinence procedure in the previous 6 months
  • Ongoing complications of prior anti-incontinence surgery
  • Received intravesical botulinum injection within the previous 12 months
  • History of an implanted nerve stimulator for incontinence
  • History of prior sling or vaginal mesh placement,
  • Previous diagnosis of interstitial cystitis, bladder cancer, or chronic pelvic pain
  • Current participation in any other conflicting interventional or OAB treatment study
  • Planning to become pregnant during the study period.
  • Pelvic radiation, history of pelvic radiation
  • Subject with 24-hour total urine volume voided greater than 3,000 ml as measured at screening period.
  • Active urinary tract or vaginal infection
  • Anatomical conditions that would prevent the introduction and use of the device, in such as significant pelvic organ prolapse,
  • Current hydronephrosis or hydroureter
  • Bladder outflow obstruction
  • Active pelvic organ
  • Urethral obstruction
  • Urinary retention or prolonged catheter use
  • Less than 12 months post-partum or currently pregnant or plan to become pregnant in the following 12 months.
  • Untreated symptomatic urinary tract infection
  • Unevaluated hematuria
  • Medical instability
  • Allergy to anesthetics as Benzocaine/Lidocaine/Tetracaine Cream (BLT Cream) used in the study
  • Not available for follow-up in 6 months
  • Participation in other research trials that could influence results of this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Device Treatment

    20 female patients with overactive bladder symptoms, aged 21 to 80 years old, inclusive from two sites.

    Device: Device Morpheus8V

Interventions

  • DeviceDevice Morpheus8V

    Assigned to be treated using the modified Morpheus8V

06

What researchers measure

Primary outcomes

  1. Change in urgency incontinence episodes after 3 month

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes.

    Time frame: 3 months

Secondary outcomes

  1. Change in urgency incontinence episodes after 1 month

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes

    Time frame: 1 month

  2. Change in urgency incontinence episodes

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes.

    Time frame: 6 months

  3. Change in urgency incontinence episodes

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes.

    Time frame: 12 months

  4. Analysis to assess the urinary frequency

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the urinary frequency.

    Time frame: 1 month

  5. Analysis to assess urinary frequency

    Change from baseline to the end of treatment in a 3-day diary analysis to assess urinary frequency.

    Time frame: 3 months

  6. Analysis to assess the urinary frequency.

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the urinary frequency. \[Time Frame: 6 months\]

    Time frame: 6 months

  7. Analysis to assess the urinary frequency.

    Change from baseline to the end of treatment in a 3-day diary analysis to assess the urinary frequency.

    Time frame: 12 months

  8. Assessment of the impact of the treatment on Overactive Bladder symptoms

    Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score \> 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence. The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.

    Time frame: 1 month

  9. Assessment of the impact of the treatment on Overactive Bladder symptoms

    Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score \> 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence. The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.

    Time frame: 3 months

  10. Assessment of the impact of the treatment on Overactive Bladder symptoms

    Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score \> 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence. The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.

    Time frame: 6 months

  11. Assessment of the impact of the treatment on Overactive Bladder symptoms

    Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score \> 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence. The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.

    Time frame: 12 months

  12. Patient-reported Pain assessment

    The subject will be asked to rate the severity from 0 to 10, with 0 equaling no symptoms and 10 equaling the worst possible symptoms. A number is obtained by measuring up to the point the subject has indicated.

    Time frame: treatment procedure

  13. Patient-reported outcome measure

    Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome.

    Time frame: 1 month

  14. Patient-reported outcome measure

    Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome.

    Time frame: 3 months

  15. Patient-reported outcome measure

    Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome.

    Time frame: 6 months

  16. Patient-reported outcome measure

    Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome.

    Time frame: 12 months

07

Study locations

3 sites
  • Mickey Karram MD
    Corona Del Mar, California 92625, United States
  • Institute for Female Pelvic Medicine
    Knoxville, Tennessee 37932, United States
  • The Hospital Infantil Universitario de San José (University Children's Hospital of San José)
    Bogota,, Colombia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.

Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 24 months is above that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 28, 2024
StartActual
Nov 10, 2023
Primary completionEst.
Nov 10, 2025
CompletionEst.
Nov 10, 2027
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06283498
Lead sponsor
InMode MD Ltd.
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Nov 10, 2023
Primary completion
Nov 10, 2025 (estimated)
Completion
Nov 10, 2027 (estimated)
Last update
Mar 18, 2025

Study contacts

Mickey Karram, MD
principal investigator · Not Affiliated

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion